$11.6 billion!

On May 10, Pfizer and Biohaven Pharmaceuticals announced that the two companies had reached a definitive agreement, in which Pfizer agreed to acquire Biohaven Pharmaceuticals and its migraine drug Nurtec for a total of approximately $16 billio.

Pfizer will commercialize NURTEC® ODT (rimegepant), an innovative dual-action migraine therapy approved for the acute treatment and attack prevention of migraine in adul.

The agreement was reached on November 9, 2021, to facilitate the commercialization of rimegepant and zavegepant outside the United Stat.

Pfizer expects to fund the deal with existing ca.

What does Biohaven do?

Biohaven is a commercial-stage biopharmaceutical company with innovative, first-in-class treatments to improve the lives of patients with debilitating neurological and neuropsychiatric disorders, including rare diseas.

Biohaven's Neuroinnovation™ portfolio includes NURTEC® ODT (rimegepant), and a broad pipeline of late-stage product candidates across five different mechanistic platforms: CGRP receptor antagonists for acute and prophylactic treatment of migraine; glutamate-modulating The effects of obsessive-compulsive disorder and spinocerebellar atax.

Biohaven holds exclusive worldwide rights to the CGRP receptor antagonist platform, including rimegepant and zavegepa.

Pfizer's proposed transaction includes the acquisition of Biohaven's calcitonin gene-related peptide (CGRP) program:

Rimegepant targets the underlying cause of migraine by reversibly blocking the CGRP receptor, thereby inhibiting the biological cascade that leads to migraine attac.

Zavegepant is a third-generation high-affinity, selective and structurally unique small molecule CGRP receptor antagonist from Biohaven's NOJECTION™ migraine platform, the only intranasal and oral CGRP receptor antagonist currently in clinical developme.

The remaining 5 preclinical CGRP portfolios

Why did Pfizer acquire Biohaven?

About 1 billion people worldwide suffer from migraines, 75% of whom are wom.

The acquisition is in line with Pfizer's legacy of "bringing life-changing breakthrough innovations to patien.

What changes will Pfizer bring to the company?

Under the terms of the agreement, Pfizer will acquire all outstanding shares of Biohaven that Pfizer does not already own for $1450 per share in ca.

Pfizer will also make payments at closing to settle Biohaven's third-party debt and redeem all outstanding shares of Biohaven's redeemable preferred sto.

After the acquisition, the new Biohaven will continue to operate under the name Biohav.

Vlad Coric said: "We are delighted to announce Pfizer's acquisition of Biohaven, acknowledging the market leadership of NURTEC® ODT, our breakthrough in migraine treatment, and the untapped potential of our CGRP franchi.

What does this acquisition mean for biotech?

It's the biotech industry's biggest M&A deal so far this year, offering a major deal to a struggling public sector that could encourage a slew of share-battered drugmakers, though Biohaven doesn't fall into that catego.

The acquisition will transform Biohaven from a new drug development company to a market-oriented pharmaceutical company that can compete with some heavyweight competitors in the fie.

In the process, they have been able to increase their market capitalization over the past year by showing investors that they have ample capit.

Now, after gaining sales experience outside the.


, Pfizer can apply its strong marketing group to Nurt.

Nick Lagunowich, global president of Pfizer Internal Medicine, said, "Given our leading scale and capabilities, including comprehensive collaboration with primary care physicians, specialists and health systems to deliver the right information at the right time, we believe Pfizer is in a good position to help the product portfolio get the most out of .

It's in a unique position in terms of potenti.

"

Summarize

Pfizer threw 16 billion US dollars, not because it made too much last year, but because Biohaven has something uniq.

In addition to its product pipeline, I believe its unique migraine drug research and development platform is also valuab.

With the current decline in the popularity of the capital market, only differentiated companies can survive better, and platform technology-based companies will have many advantag.

From Tianyan & Sanofi, Hebo & AstraZeneca, Biohaven & Merck, and now Biohaven & Pfizer, it can be seen that the value of technology platforms is gradually emergi.

This may be a greater incentive for some companies committed to developing technology platfor.

References:

https://endp.

com/pfizer-buys-biohaven-for-11-6b-going-all-in-on-cgrp-portfolio/

https://